title: New approaches to reversing oral anticoagulant therapy. Introduction.
authors: Edith A
authors: EA
authors: Nutescu
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D000991:Antithrombins / Q000009:adverse effects; D001562:Benzimidazoles / Q000009:adverse effects; D000069604:Dabigatran; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D009025:Morpholines / Q000009:adverse effects; D010949:Plasma; D011322:Primary Prevention / Q000379:methods*; D011720:Pyrazoles / Q000009:adverse effects; D011728:Pyridones / Q000009:adverse effects; D000069552:Rivaroxaban; D013876:Thiophenes / Q000009:adverse effects; D013923:Thromboembolism / Q000517:prevention & control*; D016896:Treatment Outcome; D010837:Vitamin K 1 / Q000627:therapeutic use; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D000991:Antithrombins; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D010837:Vitamin K 1; D000069552:Rivaroxaban; D000069604:Dabigatran